Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders
Radu Constantinescu(Sahlgrenska University Hospital), Björn Holmberg(Sahlgrenska University Hospital), Lars Rosengren(Sahlgrenska University Hospital), Bo Johnels(University of Gothenburg), Henrik Zetterberg(National Hospital for Neurology and Neurosurgery)
Cited by 98
Related Papers
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen
|The Lancet Neurology|2009|912
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
A multicentre validation study of the diagnostic value of plasma neurofilament light
|Nature Communications|2021|554
A Practical Guide to Immunoassay Method Validation
|Frontiers in Neurology|2015|541